GLP-1 makers Novo, Eli Lilly sued over sudden loss of vision in patients
Hundreds of patients have filed lawsuits against manufacturers of GLP-1 receptor agonists, including Ozempic, Wegovy, and Mounjaro, alleging the drugs cause a rare form of vision loss. Plaintiffs describe sudden blindness, which some sources characterize as an "eye stroke." The litigation targets companies like Novo Nordisk and Eli Lilly, claiming the medications increase the risk of this rare condition. While individual users have shared accounts of immediate sight loss, the legal actions seek to establish a direct link between the weight-loss and diabetes medications and these ocular injuries.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ Hundreds of lawsuits allege GLP-1 drugs like Ozempic, Wegovy, and Mounjaro caused vision loss.
- ✓ Plaintiffs allege GLP-1 receptor agonists increase the risk of a rare form of vision loss.
What changed
Hundreds of patients have initiated lawsuits alleging GLP-1 drugs cause a rare eye stroke.
Live updates
-
Hundreds sue GLP-1 makers over sudden vision loss
Hundreds of patients have filed lawsuits against manufacturers of GLP-1 receptor agonists, including Ozempic, Wegovy, and Mounjaro, alleging the drugs cause a rare form of vision loss. Plaintiffs describe sudden blindness, which some sources characterize as an "eye stroke." The litigation targets companies like Novo Nordisk and Eli Lilly, claiming the medications increase the risk of this rare condition. While individual users have shared accounts of immediate sight loss, the legal actions seek to establish a direct link between the weight-loss and diabetes medications and these ocular injuries.
Why it matters
GLP-1 receptor agonists are widely used for managing type 2 diabetes and obesity. These lawsuits focus on a specific, rare type of vision loss rather than common side effects. The outcome will determine if manufacturers must update warning labels regarding ocular risks.
What is confirmed
- Hundreds of lawsuits allege GLP-1 drugs like Ozempic, Wegovy, and Mounjaro caused vision loss.
- Plaintiffs allege GLP-1 receptor agonists increase the risk of a rare form of vision loss.
Still unconfirmed
- A Massachusetts man described his sudden blindness as "Boom, lights out" after taking a GLP-1 drug.
- The vision loss is linked to a rare condition described as an eye stroke.
What to watch next
- Court rulings on the admissibility of evidence linking GLP-1s to eye strokes
- Official responses or medical data releases from Novo Nordisk and Eli Lilly
- Regulatory reviews by the FDA regarding GLP-1 vision loss warnings
confidence 90%Sources used for this update (10)
- Boston 25 News — ‘Boom, lights out’: Massachusetts man shares sudden blindness journey after taking GLP-1
- USA Today — Are GLP-1s causing blindness? What we know about rare cases
- NewsNation — Patients sue GLP-1 makers over sudden loss of vision
- ABC News - Breaking News, Latest News and Videos — What GLP-1 users should know about the potential risk of a rare type of vision loss
- WSJ — Patients Sue GLP-1 Drugmakers Over Risk of Sudden Vision Loss
- The Boston Globe — Could GLP-1s be linked to a rare type of vision loss? Here’s what to know.
- Fox News — Popular weight-loss drugs face numerous lawsuits over rare ‘eye stroke’ linked to vision loss
- AZ Family — Hundreds of lawsuits allege GLP-1s like Ozempic, Wegovy, Mounjaro caused vision loss
- TODAY.com — Woman Details Losing Vision After Taking GLP-1 As Hundreds of Patients Sue Drug Companies
- nypost.com — GLP-1 drugs increase rare ‘eye stroke’ linked to vision loss, hundreds of lawsuits allege
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community